工程纳米颗粒用于非侵入性胰岛素输送,用于糖尿病的精密疗法
Gunjan Adwani1, Sharda Bharti1, Awanish Kumar1
1Department of Biotechnology, National Institute of Technology, Raipur 492010, CG, India.
International journal of biological macromolecules
|June 29, 2024
概括
工程纳米颗粒为胰岛素输送提供了一个有希望的非侵入性方法,克服了传统注射的局限性. 这一策略提高了胰岛素的生物可用性和糖尿病管理的有效性.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术 纳米技术
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病是一种全球性慢性疾病,需要胰岛素治疗.
- 目前的注射胰岛素配方存在诸如侵入性和患者不合格等挑战.
- 胰岛素降解和肠道吸收不良限制了口服生物可用性.
研究的目的:
- 审查工程纳米颗粒用于胰岛素输送.
- 为了探索各种管理路径和物理化学性质.
- 突出非侵入性口服输送作为优越的替代方案.
主要方法:
- 工程纳米颗粒用于胰岛素输送的体外,体外和体外研究.
- 分析纳米粒子的输送路径和特性.
- 关于纳米粒子介导药物输送的文献综述.
主要成果:
- 工程纳米粒子保护胰岛素免受降解,并改善肠道吸收.
- 基于纳米粒子的输送增强了胰岛素的生物可用性和治疗效果.
- 非侵入性途径,特别是口服输送,显示出显著的潜力.
结论:
- 人工制造的纳米粒子在克服胰岛素输送障碍方面是有效的.
- 纳米技术为糖尿病管理提供了精确的治疗策略.
- 这种方法对未来的药物输送创新有前途.
相关概念视频
Insulin: Biosynthesis, Chemistry, and Preparation
372
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
372
Insulin Formulations: Types and Delivery
184
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
184
Glucagon-like Receptor Agonists
313
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
313


